Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

AstraZeneca joins KRAS push in cancer with Chinese deal AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

The firm is advancing ELI-002 after seeing a positive Phase I readout this month and is expecting initial results from a randomized Phase II study this year.

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Dubbed the ‘guardian of the genome’, the p53 protein responds to DNA damage by stalling cell division, initiating DNA repair ...

RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...

Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...

Mutations in the GTPase KRAS drive proliferation of many types of tumors, and daraxonrasib (RMC-6236), which inhibits various KRAS mutants, can slow growth of pancreatic and lung cancers. Researchers ...